LLY

830.61

+2.04%↑

UNH

611.17

+1.02%↑

NVO

109.04

-0.15%↓

ABBV

176.46

-2.84%↓

MRK

101.34

-0.55%↓

LLY

830.61

+2.04%↑

UNH

611.17

+1.02%↑

NVO

109.04

-0.15%↓

ABBV

176.46

-2.84%↓

MRK

101.34

-0.55%↓

LLY

830.61

+2.04%↑

UNH

611.17

+1.02%↑

NVO

109.04

-0.15%↓

ABBV

176.46

-2.84%↓

MRK

101.34

-0.55%↓

LLY

830.61

+2.04%↑

UNH

611.17

+1.02%↑

NVO

109.04

-0.15%↓

ABBV

176.46

-2.84%↓

MRK

101.34

-0.55%↓

LLY

830.61

+2.04%↑

UNH

611.17

+1.02%↑

NVO

109.04

-0.15%↓

ABBV

176.46

-2.84%↓

MRK

101.34

-0.55%↓

Search

Johnson and Johnson

Closed

Sector Healthcare

150.38 -1.27

Overview

Share price change

24h

Current

Min

149.81

Max

152.32

Key metrics

By Trading Economics

Income

-2B

2.7B

Sales

50M

23B

P/E

Sector Avg

24.52

94.904

EPS

2.42

Dividend yield

3.142

Profit margin

11.973

Employees

131,900

EBITDA

-2.4B

5.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+16.66 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.14%

2.43%

Next Earnings

21 Jan 2025

Next Dividend date

10 Dec 2024

Next Ex Dividend date

14 Feb 2025

Market Stats

By TradingEconomics

Market Cap

-2.2B

371B

Previous open

151.65

Previous close

150.38

News Sentiment

By Acuity

32%

68%

100 / 392 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Johnson and Johnson Chart

Past performance is not a reliable indicator of future results.

Related News

28 Oct 2024, 16:07 UTC

Acquisitions, Mergers, Takeovers

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

15 Oct 2024, 19:26 UTC

Earnings

Trending: Johnson & Johnson Posts Higher-Than-Expected Sales

12 Nov 2024, 20:04 UTC

Top News

J&J Sues U.S. Over Hospital Drug-Discounting Program -- WSJ

21 Oct 2024, 15:26 UTC

Acquisitions, Mergers, Takeovers

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies -- IBD

21 Oct 2024, 09:51 UTC

Top News

Starboard Targets Another Health Company. Why Kenvue Is in Its Sights. -- Barrons.com

21 Oct 2024, 09:30 UTC

Top News

J&J's Ketamine-Derived Drug Is Taking Off -- WSJ

15 Oct 2024, 12:09 UTC

Top News
Earnings

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15 Oct 2024, 12:04 UTC

Earnings

Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered Outlook -- IBD

15 Oct 2024, 11:52 UTC

Top News
Earnings

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15 Oct 2024, 10:50 UTC

Earnings

Johnson & Johnson Stock Rises On Q3 Sales Beat And Guidance Raise -- MarketWatch

15 Oct 2024, 10:28 UTC

Top News
Earnings

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Rises. -- Barrons.com

15 Oct 2024, 10:25 UTC

Earnings

J&J Reports Strong Earnings but Talc Worries Remain -- Barrons.com

15 Oct 2024, 10:20 UTC

Earnings

J&J Earnings Beat Expectations, Aided by Prescription-Drug Sales -- WSJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 View To Adj EPS $9.88-Adj EPS $9.98 Vs Prior View $9.97-$10.07 >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $9.86-$9.96 Vs Prior View $10.00-$10.10 >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson Raises 2024 Adjusted Operational Sales Growth View to 5.7%-6.2% From Prior View 5.5%-6%>JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson Updates 2024 Guidance to Reflect Improved Perfromance and Impact From Recent Acquisition of V-Wave >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q U.S. Sales $12.91B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson Raises 2024 Operational Sales View to $89.4B-$89.8B Vs Prior View $89.2B-$89.6B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 6.4% in 3Q >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson Raises 2024 View To Sales $88.4B-$88.8B Vs Prior View $88.0B-$88.4B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q Adj EPS $2.42 >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson: Innovative Medicine 3Q Results Driven by Key Brands Such as DARZALEX, ERLEADA, TREMFYA and SPRAVATO and Continued Uptake From Recently Launched Products Including CARVYKTI, RYBREVANT, TECVAYLI and TALVEY, With 11 Assets Delivering Double-Digit Growth >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q Orthopaedics Sales $2.19B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q International Sales $9.56B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $14.58B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q Sales $22.47B >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q EPS $1.11 >JNJ

15 Oct 2024, 10:20 UTC

Earnings

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

16.66% upside

12 Months Forecast

Average 177.75 USD  16.66%

High 215 USD

Low 159 USD

Based on 14 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

6

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

152.05 / 155.5Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

100 / 392 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.